At Rush University Medical Center, we are putting your safety first. For information about COVID-19, see the latest updates. Rush accepts donations to support our response effort, staff, and patients and families.

Excellence is just the beginning.

Translate

French German Italian Portuguese Russian

Treatment Study of Non-Metastatic Desmoplastic Medulloblastoma in Children

Clinical Trial Title: 
A phase II study for the treatment of non-metastatic desmoplastic medulloblastoma in children less than 4 years of age.
Clinical Trial Protocol ID: 
16050507-CAOl
Clinical Trial Investigator Name: 
Mary Lou Schmidt, MD
Clinical Trial Protocol Description: 

The ACNS 1221 study is a single arm multi institutional trial for newly diagnosed young children (0- <4 years of age at study enrollment) with nodular desmoplastic or medulloblastoma with extensive nodularity (MO ND/MBEN medulloblastoma). The primary objective is estimating the progression-free survival distribution associated with treatment as per HITSKK 2000 protocol without intraventricular methotrexate.

Clinical Trial Eligibility Criteria: 

In order to participate you must meet the following criteria:

  • Are less than 48 months old (4 years of age) at time of definitive surgery.
  • Have been newly diagnosed and have a confirmed histologic diagnosis of nodular desmoplastic (NO) medulloblastoma or medulloblastoma with extensive nodularity (MBEN) from rapid central pathology screening review.

This is a partial list of elgibility requirements.

Clinical Trial Area: 
Pediatric Cancers and Blood Disorders
Contact Email: 
Contact Phone: 
(312) CANCER-1
Contact Name: 
Rush Cancer Center Clinical Trials Office